Applications of 5-(Boc-Amino)-1-Pentanol in Industrial Manufacturing

5-(Boc-Amino)-1-Pentanol functions as a protected amino alcohol intermediate favored in several advanced manufacturing flows requiring high selectivity and purity. Our production facilities support precise integration for downstream applications within regulated environments where consistent quality and traceability are essential.

1. Peptide Synthesis Building Blocks

Major peptide production plants utilize this raw material as a chain-elongating amino alcohol during solution-phase and solid-phase peptide synthesis. The carbamate-protected amino functionality ensures orthogonality with other protecting groups during multi-step reactions, reducing side reactions and purification requirements. Reliable process control at this stage influences biologically active peptide payloads for therapeutic and biotechnical uses.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• United States Pharmacopeia (USP) peptide synthesis guidelines
• EU GMP Part II for Intermediates
• ISO 9001:2015 Quality Management Systems

Typical usage ratio

• Applied at a 0.9–1.2 molar equivalent relative to acid or coupling partner, optimized based on target sequence and resin capacity

Downstream process integration

• Introduced during protected amino component coupling in the central elongation or capping step
• Deprotection handled post-chain assembly before bioactive peptide release and purification

Final product types

• Therapeutic peptides (injectables, orals)
• Diagnostic peptides for immunoassays
• Cosmetic bioactive oligopeptides
• Research-grade peptide libraries

2. Active Pharmaceutical Intermediate (API) Manufacturing

API production lines employ 5-(Boc-Amino)-1-Pentanol as a core building block in the route to beta- and gamma-amino alcohol-based drugs. Controlled Boc protection enables selective transformations in multi-step schemes, particularly in central nervous system agent synthesis. Robust critical control points ensure that downstream intermediates pass stringent impurity and traceability checks prior to release for final API formation.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• US FDA 21 CFR 211 (Process Control for APIs)
• European Pharmacopoeia (Ph. Eur.) chapters on intermediates
• ISO 14001:2015 Environmental Management

Typical usage ratio

• Utilized at 0.8–1.5 molar equivalents relative to other chain fragments; range adjusted for side-reaction minimization and solvent compatibility

Downstream process integration

• Engaged in alkylation or reductive amination steps after protection of other sensitive functionalities
• Final deprotection follows specific, validated protocols, often hydrogenolysis or acid treatment

Final product types

• Chiral pharmaceutical intermediates
• Beta- and gamma-amino alcohol based drug APIs
• Antidepressant precursor substances
• Intermediates for antiviral compounds

3. Fine Chemical Derivatives for Agrochemical Synthesis

Manufacturers of advanced agrochemical products value this intermediate for the targeted derivatization of amine-protected pentanols, yielding compounds with improved stability for controlled release formulations. Boc protection ensures safe manipulation under chlorination, esterification, or conjugation conditions, minimizing undesirable byproducts during crop protection agent pre-formulation. Process batch monitoring addresses regulatory residue and byproduct concerns unique to agrochemicals.

Industry compliance standards

• REACH (Regulation EU No 1907/2006)
• FAO/WHO Specifications for Plant Protection Products
• ISO 9001:2015 for chemical manufacturing
• GLP (Good Laboratory Practice) for agrochemical intermediates

Typical usage ratio

• Dosage between 5–18% w/w of total reactant mass, adjusted based on final pesticide or herbicide structure requirements

Downstream process integration

• Added to reaction vessels in alkylation or acylation steps where amine selectivity is crucial
• Deprotected and derivatized immediately before main active loading step

Final product types

• Amine-derived herbicide intermediates
• Controlled-release pesticide agents
• Stabilized insecticidal compounds
• Chiral agrochemical additives

4. Polymeric Material Functionalization for Biomedical Devices

Biomedical device manufacturers source this compound for surface functionalization and backbone modification of medical polymers. Its Boc-protected structure enables stepwise incorporation into polyurethane and polyamide chains, generating functional handles for further conjugation with bioactive or hydrophilic moieties. Controlled release and biocompatibility features depend on precise control over Boc group removal and amine exposure during downstream manufacturing.

Industry compliance standards

• ISO 13485:2016 Medical device quality management
• USP Class VI Biocompatibility Guidelines for Plastics
• 21 CFR 820 FDA Medical Device GMP
• ISO 10993-1 Biological Evaluation of Medical Devices

Typical usage ratio

• Integrated at concentrations between 0.5–4.0 wt% in polymer feed streams depending on required functionality load

Downstream process integration

• Co-polymerized prior to thermosetting or extrusion
• Deprotection and functional group exposure post-fabrication for targeted ligand or biomolecule attachment

Final product types

• Medical-grade functionalized catheters
• Surgical implant coatings
• Wound dressing polymers with controlled bioactivity
• Drug-eluting device substrates